Leoni Mollie 4

What Happened Leoni Mollie, Chief Medical Officer of Kura Oncology (KURA), sold 84,929 shares on June 18, 2026. The sales were executed in multiple open-market trades at prices ranging from $9.56 to $9.98, with a weighted average sale price of $9.82, generating approximately $834,283 in proceeds. This was a sale (not a purchase), and the shares were previously acquired through vesting of restricted stock units (RSUs) and performance RSUs.

Key Details

• Transaction date: June 18, 2026 (Form 4 filed June 22, 2026; filing appears timely).
• Price: Multiple trades at $9.56–$9.98; weighted average $9.82.
• Shares sold: 84,929; proceeds ≈ $834,283.
• Shares acquired: Sold shares were from RSUs and performance RSUs that vested between Jan 26, 2022 and Jan 26, 2026.
• Trading plan: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 19, 2026.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote on pricing: The filing reports a weighted average; the filer offered to provide the breakdown of individual trade prices upon request.

Context Sales of vested RSUs executed under a 10b5-1 plan are commonly pre-planned liquidity events rather than reactive trades based on new company information. For retail investors, purchases often signal stronger insider conviction than routine sales; this transaction appears to be a planned disposition of vested equity rather than a direct signal about Kura Oncology’s near-term prospects.